Moderna Makes History as FDA Approves the World’s First mRNA-Based Seasonal Flu Vaccine for Millions of Adults
The United States has approved Moderna's first mRNA-based seasonal influenza vaccine, marking a historic milestone for the biotechnology company and the broader future of vaccine development. The approval makes the new shot, mFlusiva, the first flu vaccine to use messenger RNA (mRNA) technology—the same platform that helped produce COVID-19 vaccines in record time during the pandemic. The decision by the U.S. Food and Drug Administration (FDA) is being viewed as […]
